LGNYZ Financials Tuesday, July 15, 2014 06:16:40 A

LGNYZ Financials Tuesday, July 15, 2014 06:16:40 AM
Ligand Pharmaceuticals Incorporated
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 48,973 31,388 30,037 23,538
Cost of Revenue 5,732 3,601 4,909 -
Gross Profit 43,241 27,787 25,128 23,538
Operating Expenses
Research and Development 9,274 10,790 10,291 22,067
Sales, General and Admin. 17,984 15,782 12,881 11,127
Non-Recurring Items 1,040 1,022 2,834 19,648
Other - - - -
Operating Income 14,943 193 (878) (29,304)
Income From Continuing Operations
Add'l Income/Expense Items (3,660) (1,134) (383) 13,519
Earnings Before Interest and Tax 11,283 (941) (1,261) (15,403)
Interest Expense 2,077 2,924 2,297 -
Earnings Before Tax 9,206 (3,865) (3,558) (15,403)
Income Tax 374 (1,191) (13,270) (2,617)
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations 8,832 (2,674) 9,712 (12,786)
Non Recurring Events
Discontinued Operations 2,588 2,147 3 2,413
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 11,420 (527) 9,715 (10,373)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 11,420 (527) 9,715 (10,373)